Segmented Controlled Release Dosage Form for Baclofen
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dosage forms of baclofen, particularly immediate release forms, require frequent administration due to rapid clearance and limited absorption window, leading to suboptimal therapeutic efficacy and convenience for treating spasticity in conditions like multiple sclerosis.
Innovation Solution
A controlled release oral dosage form comprising a GABAB receptor agonist, such as (R)-baclofen, with a semipermeable membrane and water-swellable excipients, designed for once or twice daily administration, enhancing bioabsorption and maintaining therapeutic levels for an extended period without increasing doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release dosage form is used, then rapid drug release is achieved, but frequent administration is required due to rapid clearance
Solution Approach 1:
The dosage form is segmented into multiple functional layers: an immediate release layer for rapid initial drug delivery, a controlled release layer for sustained drug release over time, and an extended release layer for prolonged therapeutic effect. This segmentation allows different portions of the drug to be released at different rates, resolving the contradiction between rapid release and extended duration.
Solution Approach 2:
The patent employs multiple release profiles with different kinetic parameters (zero-order, first-order, Higuchi, Hixon-Crowell) to control drug release at different stages. By changing release parameters over time through the layered structure, the system achieves both rapid initial release and prolonged therapeutic duration without requiring frequent administration.
2Duration of action of moving object
If controlled release dosage form is used, then administration frequency is reduced, but bioabsorption efficiency may be compromised
Solution Approach 1:
The layered dosage form segments drug release into immediate, controlled, and extended phases, ensuring that sufficient drug reaches systemic circulation quickly (improving bioabsorption reliability) while maintaining therapeutic levels over an extended period (improving duration). The immediate release layer ensures rapid initial absorption, preventing the reliability issue associated with controlled release formulations.
Solution Approach 2:
The dosage form uses composite material structures with different release characteristics in each layer. This composite approach combines the advantages of rapid release (improving bioabsorption) with sustained release (improving duration), resolving the contradiction between reliability of absorption and therapeutic duration.
3Reliability
If frequent administration is required, then therapeutic levels are maintained, but patient convenience and compliance deteriorate
Solution Approach 1:
The multi-layer dosage form provides continuous drug release through its immediate, controlled, and extended release layers, maintaining therapeutic levels continuously without requiring frequent re-dosing. This continuous action approach allows once-daily or twice-daily administration while maintaining reliable therapeutic levels, greatly improving patient convenience and compliance.
4Reliability
If dose is increased to compensate for rapid clearance, then therapeutic efficacy improves, but adverse events increase
Solution Approach 1:
The dosage form dynamically adjusts drug release rates through its layered structure, providing high initial release for rapid therapeutic effect followed by gradually decreasing release rates. This dynamic release profile maintains therapeutic efficacy while avoiding the need for continuously high doses, thereby reducing adverse events associated with high dosing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The controlled release dosage form provides improved bioabsorption and prolonged therapeutic effects, offering enhanced efficacy and safety profiles compared to traditional forms, with a positive food effect that can alter dosing regimens and reduce adverse events.
Implementation Method 1
a controlled release oral dosage form comprising a GABAB receptor agonist... with a semipermeable membrane
Implementation Method 2
water-swellable excipients
Implementation Method 3
The core comprises at least one GABAB receptor agonist and at least one water-swellable excipient
Data Source
AI summary
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.